^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Squamous Cell Skin Cancer

Related cancers:
No biomarker
Squamous Cell Skin Cancer
pembrolizumab
Sensitive
:
A1
No biomarker
Squamous Cell Skin Cancer
cemiplimab
Sensitive
:
A1
No biomarker
Squamous Cell Skin Cancer
celecoxib
Resistant
:
A2
No biomarker
Squamous Cell Skin Cancer
carboplatin + paclitaxel
Sensitive
:
A2
No biomarker
Squamous Cell Skin Cancer
carboplatin
Sensitive
:
A2
No biomarker
Squamous Cell Skin Cancer
cisplatin + 5-fluorouracil
Sensitive
:
A2
No biomarker
Squamous Cell Skin Cancer
cisplatin
Sensitive
:
A2
No biomarker
Squamous Cell Skin Cancer
capecitabine
Sensitive
:
A2
No biomarker
Squamous Cell Skin Cancer
cetuximab
Sensitive
:
A2
PD-L1 expression
Squamous Cell Skin Cancer
pembrolizumab
Sensitive
:
C2
CCND1 overexpression
Squamous Cell Skin Cancer
everolimus
Resistant
:
C3
MSH6 mutation + MLH1 mutation + MSI-H
Squamous Cell Skin Cancer
pembrolizumab
Sensitive
:
C4
TMB-H + PD-L1 expression
Squamous Cell Skin Cancer
pembrolizumab + panitumumab
Sensitive
:
C4
ERBB3 R135C + TMB-H
Squamous Cell Skin Cancer
nivolumab + lapatinib
Sensitive
:
C4
SRC amplification
Squamous Cell Skin Cancer
pembrolizumab
Sensitive
:
C4
TMB-H
Squamous Cell Skin Cancer
pembrolizumab
Sensitive
:
C4
TP53 mutation
Squamous Cell Skin Cancer
pembrolizumab
Sensitive
:
C4
BRCA2 deletion
Squamous Cell Skin Cancer
pembrolizumab
Sensitive
:
C4
NGFR overexpression
Squamous Cell Skin Cancer
5-fluorouracil
Sensitive
:
D
NGFR overexpression
Squamous Cell Skin Cancer
cisplatin
Sensitive
:
D